Elcelyx Therapeutics, Inc.

Amylin Pharmaceuticals, Inc.

Astrazeneca Pharmaceuticals LP

Anji Pharma (us) LLC

Ambra Bioscience LLC

Anji Pharmaceuticals Inc.

Nazura Biohealth, Inc.

Anji Pharma LLC

Alain D Baron

Mark S Fineman

Nigel R A Beeley

Andrew A Young

Soumitra S Ghosh

Odile Esther Levy

Michael R Hanley

Christopher Joseph Soares

David Geoffrey Parkes

Mary Erickson

Christine Marie Mack

Carolyn M Jodka

Lawrence J D'Souza

Richard A Pittner

Diana Y Lewis

Martin R Brown

Samuel Janssen

Christopher R G Jones

Thao Le

David R Hathaway

Christen M Anderson

Richard J Roman

Ved Srivastava

Jonathan David Roth

Nigel R Beeley

Dennis Kim

Matthew Wintle

David G Maggs

Christopher R J Jones

Terri Kim

Christopher R Jones

Christopher RG Jones

Soumitra G Ghosh

Mahesh Mistry

Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.

Compositions and methods for treating metabolic disorders

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

Biguanide compositions and methods of treating metabolic disorders

Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

Chemosensory receptor ligand-based therapies

Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release.

Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

Provided herein are compositions and methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions with chemosensory receptor ligands. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention.

Growing community of inventors

San Diego, CA, United States of America

Alain D Baron